NO20022557L - 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler - Google Patents

2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler

Info

Publication number
NO20022557L
NO20022557L NO20022557A NO20022557A NO20022557L NO 20022557 L NO20022557 L NO 20022557L NO 20022557 A NO20022557 A NO 20022557A NO 20022557 A NO20022557 A NO 20022557A NO 20022557 L NO20022557 L NO 20022557L
Authority
NO
Norway
Prior art keywords
immunosuppressants
compounds useful
diaminopyrimidine compounds
compounds
alkylaminocarbonylamino
Prior art date
Application number
NO20022557A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022557D0 (no
Inventor
Todd Andrew Blumenkopf
Eileen Elliott Mueller
Eric Jan Roskamp
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20022557D0 publication Critical patent/NO20022557D0/no
Publication of NO20022557L publication Critical patent/NO20022557L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20022557A 1999-11-30 2002-05-29 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler NO20022557L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (2)

Publication Number Publication Date
NO20022557D0 NO20022557D0 (no) 2002-05-29
NO20022557L true NO20022557L (no) 2002-05-29

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022557A NO20022557L (no) 1999-11-30 2002-05-29 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler

Country Status (33)

Country Link
EP (1) EP1242403B1 (ja)
JP (1) JP3955468B2 (ja)
KR (1) KR20020059826A (ja)
CN (1) CN1402720A (ja)
AP (1) AP2002002530A0 (ja)
AT (1) ATE315036T1 (ja)
AU (1) AU1047601A (ja)
BG (1) BG106695A (ja)
BR (1) BR0015995A (ja)
CA (1) CA2392971C (ja)
CO (1) CO5261519A1 (ja)
CZ (1) CZ20021703A3 (ja)
DE (1) DE60025385T2 (ja)
EA (1) EA200200411A1 (ja)
EE (1) EE200200275A (ja)
ES (1) ES2253266T3 (ja)
GT (1) GT200000200A (ja)
HN (1) HN2000000264A (ja)
HU (1) HUP0203300A3 (ja)
IL (1) IL149103A0 (ja)
IS (1) IS6339A (ja)
MA (1) MA26846A1 (ja)
MX (1) MXPA02005350A (ja)
NO (1) NO20022557L (ja)
OA (1) OA12097A (ja)
PA (1) PA8506801A1 (ja)
PE (1) PE20010900A1 (ja)
PL (1) PL355946A1 (ja)
SV (1) SV2002000231A (ja)
TN (1) TNSN00232A1 (ja)
TR (1) TR200201431T2 (ja)
UY (1) UY26455A1 (ja)
WO (1) WO2001040215A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
HUP0302669A3 (en) * 2000-08-31 2004-03-29 Pfizer Prod Inc Pyrazole derivatives and pharmaceutical compositions containing them for treating diseases comprising abnormal cell growth and neurodegenerative diseases
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
KR20060133552A (ko) * 2004-01-16 2006-12-26 노파르티스 아게 2,4-디아미노피리미딘 및 심장근육발생 유도를 위한 그의용도
ATE512144T1 (de) * 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7622463B2 (en) 2006-02-14 2009-11-24 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
MX2008011661A (es) * 2006-03-16 2008-09-22 Novartis Ag Compuestos organicos heterociclicos para el tratamiento de melanoma en particular.
JP2010526825A (ja) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
WO2009051119A1 (ja) 2007-10-16 2009-04-23 Daiichi Sankyo Company, Limited ピリミジルインドリン化合物
AU2010299579A1 (en) 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
EP3055301B1 (en) * 2013-10-07 2019-11-20 Kadmon Corporation, LLC (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
TR200201431T2 (tr) 2002-09-23
HUP0203300A2 (hu) 2003-02-28
EA200200411A1 (ru) 2002-10-31
CZ20021703A3 (cs) 2003-06-18
EP1242403A1 (en) 2002-09-25
AP2002002530A0 (en) 2002-06-30
AU1047601A (en) 2001-06-12
OA12097A (en) 2006-05-04
TNSN00232A1 (fr) 2005-11-10
UY26455A1 (es) 2001-07-31
MXPA02005350A (es) 2002-12-11
DE60025385D1 (de) 2006-03-30
CO5261519A1 (es) 2003-03-31
KR20020059826A (ko) 2002-07-13
PE20010900A1 (es) 2001-09-08
GT200000200A (es) 2002-05-23
CN1402720A (zh) 2003-03-12
ES2253266T3 (es) 2006-06-01
MA26846A1 (fr) 2004-12-20
PA8506801A1 (es) 2002-04-25
JP2003515602A (ja) 2003-05-07
NO20022557D0 (no) 2002-05-29
EE200200275A (et) 2003-10-15
BG106695A (bg) 2002-12-29
HN2000000264A (es) 2001-05-21
IS6339A (is) 2002-04-12
DE60025385T2 (de) 2006-08-24
IL149103A0 (en) 2002-11-10
CA2392971C (en) 2008-10-07
HUP0203300A3 (en) 2003-10-28
JP3955468B2 (ja) 2007-08-08
WO2001040215A1 (en) 2001-06-07
PL355946A1 (en) 2004-05-31
BR0015995A (pt) 2002-08-06
EP1242403B1 (en) 2006-01-04
CA2392971A1 (en) 2001-06-07
ATE315036T1 (de) 2006-02-15
SV2002000231A (es) 2002-07-16

Similar Documents

Publication Publication Date Title
NO20022557L (no) 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler
RS51607B (sr) Novi lekovi za tretiranje hroničnog opstruktivnog oboljenja pluća
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20074698L (no) Pyrazinylsubstituerte piperazinpiperidiner med CXCR3-antagonistaktivitet
TW200640906A (en) Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
GB0226931D0 (en) Chemical compounds
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
TW200640901A (en) Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
HUP0300618A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE60335911D1 (de) Isochinolinonderivate und deren verwendung als medikamente
NO20004624D0 (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
MX2009006871A (es) Compuestos heterociclicos con actividad antagonista de cxcr3.
CA2146429A1 (en) 25-carboxylic acid derivatives in the vitamin d series, method of producing them, intermediate products for this method, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicines
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
NO960653L (no) Nytt, farmasöytisk middel for oral administrering omfattende progesteron og en polyetylenglykol sammen med en eksipiens
NO964667L (no) Purin-6-on-derivater
NO996108L (no) 9-oksinerytromycinderivater
TR200000223T2 (tr) XA faktörünü engelleyen heterosiklik türevler
ATE424893T1 (de) Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
NO982238D0 (no) Substituerte 4-(1H-benzimidazol-2-yl-amino)piperidiner som er anvendbare for behandling av allergiske sykdommer
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application